Skip to Main Content

TScan Therapeutics on Wednesday announced a $30 million deal with Swiss pharma giant Novartis (NVS) to develop therapies to treat a type of kidney cancer.

The Waltham, Mass., biopharmaceutical company is working to develop treatments that focus on T cells in the body’s immune system response. By harnessing information from T cells in recovering cancer patients, TScan aims to essentially reprogram the same cells in other patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!